We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
- Authors
Bornhäuser, Martin; Kröger, Nicolaus; Schwerdtfeger, Rainer; Schafer-Eckart, Karin; Sayer, Herbert G.; Scheid, Christoph; Stelljes, Mattias; Kienast, Joachim; Mundhenk, Peter; Fruehauf, Stefan; Kiehl, Michael G.; Wandt, Hannes; Theuser, Catrin; Ehninger, Gerhard; Zander, Axel R.
- Abstract
Objective: To analyse the results of allogeneic haematopoietic cell transplantation (HCT) in patients with advanced stages of Philadelphia chromosome-positive chronic myelogenous leukaemia (CML) who had previously been treated with imatinib mesylate (IM). Methods: We analysed the outcome of 61 patients with CML who had received allogeneic HCT from sibling ( n = 18) or unrelated ( n = 43) donors after having been treated with IM. Forty-one patients had received IM because of accelerated or blast phase CML. Conditioning therapy contained standard doses of busulfan ( n = 25) or total-body irradiation ( n = 20) in conjunction with cyclophosphamide in the majority of cases. Sixteen patients received dose-reduced conditioning with fludarabine-based regimens. Results: The incidence of grades II–IV and III–IV graft-versus-host disease was 66% and 38% respectively. The probability of overall survival (OS), disease-free survival (DFS) and relapse at 18 months for the whole patient cohort were 37%, 33% and 24% respectively. The probability of non-relapse mortality (NRM) at 100 d and 12 months was 30% and 46% respectively. Univariate analysis showed that fludarabine-based conditioning therapy, age ≥40 yr and >12 months interval between diagnosis and transplantation were associated with a significantly lower OS and DFS and a higher NRM. Conclusion: These data suggest that although pretreatment with IM is not an independent negative prognostic factor, it cannot improve the dismal prognosis of CML patients at high risk for transplant-related mortality.
- Subjects
STEM cell transplantation; CELL transplantation; MYELOID leukemia; BONE marrow diseases; NONLYMPHOID leukemia
- Publication
European Journal of Haematology, 2006, Vol 76, Issue 1, p9
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/j.0902-4441.2005.t01-1-EJH2321.x